Foresite Capital Management IV, LLC - Q2 2020 holdings

$205 Million is the total value of Foresite Capital Management IV, LLC's 12 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 100.0% .

 Value Shares↓ Weighting
QURE ExituniQure N.V.$0-19,082
-100.0%
-1.12%
KNSA ExitKiniksa Pharmaceuticals, Ltd.$0-65,000
-100.0%
-1.24%
BLUE Exitbluebird bio, Inc.$0-50,000
-100.0%
-2.83%
AERI ExitAerie Pharmaceuticals, Inc.$0-227,717
-100.0%
-3.79%
BHVN ExitBiohaven Pharmaceutical Holding Company Ltd.$0-156,355
-100.0%
-6.56%
INSM ExitInsmed Incorporated$0-678,322
-100.0%
-13.40%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CymaBay Therapeutics, Inc.23Q3 202314.8%
Aclaris Therapeutics, Inc.18Q3 202318.9%
Kura Oncology, Inc.16Q3 202311.7%
Kinnate Biopharma Inc.12Q3 202341.8%
Myokardia, Inc.12Q3 202017.8%
Pharvaris N.V.11Q3 202343.4%
Cytokinetics Incorporated11Q2 202131.6%
Lyell Immunopharma, Inc.10Q3 202329.2%
Insmed Incorporated10Q1 202019.2%
Biohaven Pharmaceutical Holding Company Ltd.9Q1 202014.5%

View Foresite Capital Management IV, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-05-15
42024-04-05
13F-HR2024-02-13
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
42023-05-10
42023-02-22
13F-HR2023-02-13
13F-HR2022-11-14

View Foresite Capital Management IV, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management IV, LLC's holdings